Today, he and his colleagues published a paper in the New England Journal of Medicine about a new way to slow and possibly even stop the progression of type 1 diabetes, also known as juvenile-onset diabetes.
The approach uses the drug Rituxan, normally indicated to treat non-hodgkins lymphoma and rheumatoid arthritis.
From Reuters:
"What this study does is open the door to a whole new way to approaching type 1 diabetes," Dr. Mark Pescovitz of Indiana University, who led the study, said in a telephone interview.
Rituxan, known generically as rituximab, is made by Genentech, a unit of Roche Holding AG and Biogen Idec Inc. It was designed to wipe out immune cells known as B lymphocytes, which proliferate out of control in lymphoma.
The same cells are also involved in the autoimmune destruction of healthy cells and tissue seen in rheumatoid arthritis and, in theory, in juvenile diabetes.
Usually, by the time diabetes symptoms appear, 80 to 90 percent of those insulin-producing cells have been destroyed. The Pescovitz team gave Rituxan hoping to save the remaining cells.
The treatment worked at first and the body produced more insulin. But over time, the effects faded, and insulin production began to decline at the same rate as among people who received placebo.
Pescovitz said he was not disappointed. Further tests will show if repeated treatments with Rituxan or newer drugs that also eliminate B lymphocytes will keep insulin production up.
No comments:
Post a Comment